Silent cerebral ischemic lesions after catheter ablation of atrial fibrillation in patients on 5 types of periprocedural oral anticoagulation - Predictors of diffusion-weighted imaging-positive lesions and follow-up magnetic resonance imaging

Circulation Journal

Volumn 80, Issue 4, 2016, Pages 870-877

  Nakamura, Kohki ^a   Naito, Shigeto ^a   Sasaki, Takehito ^a   Minami, Kentaro ^a   Take, Yutaka ^a   Goto, Eri ^a   Shimizu, Satoru ^a   Yamaguchi, Yoshiaki ^a   Suzuki, Naoko ^a   Yano, Toshiaki ^a   Senga, Michiharu ^a   Kumagai, Koji ^a   Kaseno, Kenichi ^b   Funabashi, Nobusada ^c   Oshima, Shigeru ^a  

^a Gunma Prefectural Cardiovascular Center   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial fibrillation; Catheter ablation; Magnetic resonance imaging; Non vitamin K antagonist oral anticoagulant; Silent cerebral ischemic lesion

Indexed keywords

APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; HEPARIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; DABIGATRAN;

ABLATION CATHETER; ADULT; AGED; APPLICATION SITE BLEEDING; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CARDIOVERSION; CATHETER ABLATION; CATHETER SHEATH; CHADS2 SCORE; CONTROLLED STUDY; CRYOABLATION; DIFFUSION WEIGHTED IMAGING; ELECTROANATOMIC MAPPING SYSTEM; FEMALE; GROIN HEMATOMA; HEART TAMPONADE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MAPPING CATHETER; MEDICAL DEVICE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PERICARDIAL EFFUSION; RETROPERITONEAL HEMORRHAGE; RETROSPECTIVE STUDY; RISK FACTOR; ADVERSE EFFECTS; BRAIN INFARCTION; DIAGNOSTIC IMAGING; FOLLOW UP; MIDDLE AGED; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; PROCEDURES;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN INFARCTION; CATHETER ABLATION; DABIGATRAN; DIFFUSION MAGNETIC RESONANCE IMAGING; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES;

EID: 84961578399     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-1368     Document Type: Article

References (41)

1. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation: Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS): Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 2012; 9: 632-696.
2. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-38.
3. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: Comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007; 116: 2531-2534.
4. Hussein AA, Martin DO, Saliba W, Patel D, Karim S, Batal O, et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: A safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 2009; 6: 1425-1429.
5. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. Circulation 2010; 121: 2550-2556.
6. Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: Evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012; 5: 302-311.
7. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: Results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014; 129: 2638-2644.
8. Santarpia G, Curcio A, Sibilio G, Indolfi C. Clinical significance of non-vitamin K antagonist oral anticoagulants in the management of atrial fibrillation. Circ J 2015; 79: 914-923.
9. Inoue K, Murakawa Y, Nogami A, Shoda M, Naito S, Kumagai K, et al. Current status of catheter ablation for atrial fibrillation: Updated summary of the Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF). Circ J 2014; 78: 1112-1120.
10. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015; 36: 1805-1811.
11. Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S, et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study. Heart Rhythm 2015; 12: 1162-1168.
12. Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V, et al. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol 2015; 115: 47-51.
13. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2014; 63: 982-988.
14. Maddox W, Kay GN, Yamada T, Osorio J, Doppalapudi H, Plumb VJ, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol 2013; 24: 861-865.
15. Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2013; 6: 460-466.
16. Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013; 10: 483-489.
17. Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 2012; 76: 2337-2342.
18. Lickfett L, Hackenbroch M, Lewalter T, Selbach S, Schwab JO, Yang A, et al. Cerebral diffusion-weighted magnetic resonance imaging: A tool to monitor the thrombogenicity of left atrial catheter ablation. J Cardiovasc Electrophysiol 2006; 17: 7.
19. Schrickel JW, Lickfett L, Lewalter T, Mittman-Braun E, Selbach S, Strach K, et al. Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace 2010; 12: 52-57.
20. Gaita F, Caponi D, Pianelli M, Scaglione M, Toso E, Cesarani F, et al. Radiofrequency catheter ablation of atrial fibrillation: A cause of silent thromboembolism?: Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 2010; 122: 1667-1673.
21. Gaita F, Leclercq JF, Schumacher B, Scaglione M, Toso E, Halimi F, et al. Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: Comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Electrophysiol 2011; 22: 961-968.
22. Deneke T, Shin DI, Balta O, Bunz K, Fassbender F, Mugge A, et al. Postablation asymptomatic cerebral lesions: Long-term follow-up using magnetic resonance imaging. Heart Rhythm 2011; 8: 1705-1711.
23. Neumann T, Kuniss M, Conradi G, Janin S, Berkowitsch A, Wojcik M, et al. MEDAFI-Trial (Micro-embolization during ablation of atrial fibrillation): Comparison of pulmonary vein isolation using cryoballoon technique vs. radiofrequency energy. Europace 2011; 13: 37-44.
24. Herrera Siklody C, Deneke T, Hocini M, Lehrmann H, Shin DI, Miyazaki S, et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: Comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol 2011; 58: 681-688.
25. Scaglione M, Blandino A, Raimondo C, Caponi D, Di Donna P, Toso E, et al. Impact of ablation catheter irrigation design on silent cerebral embolism after radiofrequency catheter ablation of atrial fibrillation: Results from a pilot study. J Cardiovasc Electrophysiol 2012; 23: 801-805.
26. Rillig A, Meyerfeldt U, Tilz RR, Talazko J, Arya A, Zvereva V, et al. Incidence and long-term follow-up of silent cerebral lesions after pulmonary vein isolation using a remote robotic navigation system as compared with manual ablation. Circ Arrhythm Electrophysiol 2012; 5: 15-21.
27. Haeusler KG, Koch L, Herm J, Kopp UA, Heuschmann PU, Endres M, et al. 3 Tesla MRI-detected brain lesions after pulmonary vein isolation for atrial fibrillation: Results of the MACPAF study. J Cardiovasc Electrophysiol 2013; 24: 14-21.
28. Schmidt B, Gunawardene M, Krieg D, Bordignon S, Furnkranz A, Kulikoglu M, et al. A prospective randomized single-center study on the risk of asymptomatic cerebral lesions comparing irrigated radiofrequency current ablation with the cryoballoon and the laser balloon. J Cardiovasc Electrophysiol 2013; 24: 869-874.
29. Di Biase L, Gaita F, Toso E, Santangeli P, Mohanty P, Rutledge N, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm 2014; 11: 791-798.
30. Martinek M, Sigmund E, Lemes C, Derndorfer M, Aichinger J, Winter S, et al. Asymptomatic cerebral lesions during pulmonary vein isolation under uninterrupted oral anticoagulation. Europace 2013; 15: 325-331.
31. Wissner E, Metzner A, Neuzil P, Petru J, Skoda J, Sediva L, et al. Asymptomatic brain lesions following laserballoon-based pulmonary vein isolation. Europace 2014; 16: 214-219.
32. von Bary C, Deneke T, Arentz T, Schade A, Lehrmann H, Eissnert C, et al. Silent cerebral events as a result of left atrial catheter ablation do not cause neuropsychological sequelae: A MRI-controlled multicenter study. J Interv Card Electrophysiol 2015; 43: 217-226.
33. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. Circ J 2014; 78: 1997-2021.
34. Burdette JH, Ricci PE, Petitti N, Elster AD. Cerebral infarction: Time course of signal intensity changes on diffusion-weighted MR images. AJR Am J Roentgenol 1998; 171: 791-795.
35. Fiebach JB, Schellinger PD, Jansen O, Meyer M, Wilde P, Bender J, et al. CT and diffusion-weighted MR imaging in randomized order: Diffusion-weighted imaging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke 2002; 33: 2206-2210.
36. Deneke T, Jais P, Scaglione M, Schmitt R, di Biase L, Christopoulos G, et al. Silent cerebral events/lesions related to atrial fibrillation ablation: A clinical review. J Cardiovasc Electrophysiol 2015; 26: 455-463.
37. Deneke T, Nentwich K, Schmitt R, Christhopoulos G, Krug J, Di Biase L, et al. Exchanging catheters over a single transseptal sheath during left atrial ablation is associated with a higher risk for silent cerebral events. Indian Pacing Electrophysiol J 2014; 14: 240-249.
38. Perzborn E, Heitmeier S, Buetehorn U, Laux V. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. J Thromb Haemost 2014; 12: 1054-1065.
39. Furugohri T, Shiozaki Y, Muramatsu S, Honda Y, Matsumoto C, Isobe K, et al. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. Eur J Pharmacol 2005; 514: 35-42.
40. Albach FN, Brunecker P, Usnich T, Villringer K, Ebinger M, Fiebach JB, et al. Complete early reversal of diffusion-weighted imaging hyperintensities after ischemic stroke is mainly limited to small embolic lesions. Stroke 2013; 44: 1043-1048.
41. Kranz PG, Eastwood JD. Does diffusion-weighted imaging represent the ischemic core? An evidence-based systematic review. AJNR Am J Neuroradiol 2009; 30: 1206-1212.